A genetic analysis led by Dr. Erik Knudsen (left) and Dr. Agnieszka Witkiewicz suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. Credit: UT Southwestern Medical Center
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. The findings support a precision approach to treating pancreatic cancer, the fourth most deadly cancer for both men and women.
A comprehensive DNA sequencing of pancreatic cancer cases revealed not only a plethora of damaged genes, but potential diagnostic biomarkers that could help identify those with longer or shorter survival, and provide opportunity for new therapeutic interventions. The new findings are published in Nature Communications.
"We identified a wealth of genetic diversity, including multiple mutated genes that were previously unknown to pancreatic cancer ? an important step in gaining a better understanding of this difficult and particularly deadly disease," said lead author Dr. Agnieszka Witkiewicz, Associate Professor of Pathology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. "Importantly, the team was able to identify several genes that may be able to help us to predict outcomes in certain circumstances or serve as good candidates for therapeutic efforts."
Researchers have long hoped that genetic analysis would provide insight into the biology of pancreatic cancer and define new targets for more effective treatment. Achieving this goal has been hampered by the technical difficulty of isolating pure cancer cells out of the tumor tissue that contains both tumor cells as well as normal cells. The new study overcame this limitation by selectively dissecting cancer cells from pieces of tumor tissue. This method was applied to specifically determine the genetic features of 109 different tumors.
The data showed that the genetic architecture of pancreatic cancer is complex, and each patient's tumor was found to be unique. The genetic features illuminated ways in which the disease arises, defined events associated with survival, and yielded potential targets for therapeutic intervention.
"While we suspect that genetics can be used as the basis of targeted treatments, this point will only be proven through extensive research and clinical studies, hopefully leading to improved outcomes for patients," said senior author Dr. Erik Knudsen, Professor of Pathology, and member of the Simmons Cancer Center who holds the Dr. Charles T. Ashworth Professorship in Pathology. "I am considerably more optimistic of the utility of a genetically targeted therapy for pancreatic cancer today than when we began this work."
Pancreatic cancer is particularly difficult to treat, and is often diagnosed at a late stage when it is no longer amenable to surgical removal. Chemotherapy has a modest effect, and unfortunately the disease progresses in the vast majority of cases. Therefore, new therapeutic regimens are urgently needed.
"Pancreatic cancer will surpass breast and prostate to become the third-leading cause of cancer-related deaths in the next 15 years. If we want to change the death rate, we need to increase the investment in understanding the biology of pancreatic cancer and identifying novel treatment strategies," said co-author and pancreatic cancer surgeon Dr. Michael Choti, Chairman of Surgery, who holds the Hall and Mary Lucile Shannon Distinguished Chair in Surgery.
The study identified a multitude of events that could be selectively targeted in the context of individual pancreatic tumors. For example, the study defined cases of pancreatic cancer that are driven by a gene called BRAF, for which there are FDA-approved drugs, and showed that such drugs were selectively effective against BRAF-mutated pancreatic cancer cells. Similarly, they defined deficits in other features of the tumor cell that can be treated by select drugs.
While these are exciting discoveries for a disease with such a poor prognosis, Dr. Witkiewicz voiced caution.
"Most pancreatic cancers exhibit multiple genetic alterations; therefore, it is likely that combination approaches targeting multiple pathways will be required for effective disease control," she said.
Explore further: Promising new strategy to halt pancreatic cancer metastasis
Medical Xpress on facebook
Related Stories
Promising new strategy to halt pancreatic cancer metastasis
Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.
Researchers learning more about deadly pancreatic cancer
(HealthDay)—Scientists are working to find new ways to treat pancreatic cancer, one of the deadliest types of cancer in the United States.
What makes pancreatic cancer so aggressive? New study sheds light
New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.
Pancreatic cancer has four distinct types
Researchers have found that pancreatic cancer can be split into four unique types, a discovery that could be used to improve treatments for the disease, according to a study published in Nature.
Researchers identify pancreatic cancer patients who benefit from personalized treatment
Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.
Recommended for you
A downward trend for new cases of pediatric melanoma
Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has ...
We may be looking at wrong mutation for breast cancer treatment
A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to research published in open access journal Genome Medicine.
Genetic screening could improve breast cancer prevention
A test for a wide range of genetic risk factors could improve doctors' ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.
Biologists identify brain tumor weakness
Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.
No association between lung cancer risk in women and reproductive history or hormone use
The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for ...
Tumor cells that mimic blood vessels could help breast cancer spread to other sites
Imitation may be the sincerest form of flattery, but it can also have deadly consequences, at least when it comes to tumor cells.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
A genetic analysis led by Dr. Erik Knudsen (left) and Dr. Agnieszka Witkiewicz suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. Credit: UT Southwestern Medical Center
A genetic analysis led by UT Southwestern Medical Center researchers suggests that most pancreatic cancers harbor genetic alterations that could be targeted by existing drugs, using their genetic features as a roadmap for treatment. The findings support a precision approach to treating pancreatic cancer, the fourth most deadly cancer for both men and women.
A comprehensive DNA sequencing of pancreatic cancer cases revealed not only a plethora of damaged genes, but potential diagnostic biomarkers that could help identify those with longer or shorter survival, and provide opportunity for new therapeutic interventions. The new findings are published in Nature Communications.
"We identified a wealth of genetic diversity, including multiple mutated genes that were previously unknown to pancreatic cancer ? an important step in gaining a better understanding of this difficult and particularly deadly disease," said lead author Dr. Agnieszka Witkiewicz, Associate Professor of Pathology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. "Importantly, the team was able to identify several genes that may be able to help us to predict outcomes in certain circumstances or serve as good candidates for therapeutic efforts."
Researchers have long hoped that genetic analysis would provide insight into the biology of pancreatic cancer and define new targets for more effective treatment. Achieving this goal has been hampered by the technical difficulty of isolating pure cancer cells out of the tumor tissue that contains both tumor cells as well as normal cells. The new study overcame this limitation by selectively dissecting cancer cells from pieces of tumor tissue. This method was applied to specifically determine the genetic features of 109 different tumors.
The data showed that the genetic architecture of pancreatic cancer is complex, and each patient's tumor was found to be unique. The genetic features illuminated ways in which the disease arises, defined events associated with survival, and yielded potential targets for therapeutic intervention.
"While we suspect that genetics can be used as the basis of targeted treatments, this point will only be proven through extensive research and clinical studies, hopefully leading to improved outcomes for patients," said senior author Dr. Erik Knudsen, Professor of Pathology, and member of the Simmons Cancer Center who holds the Dr. Charles T. Ashworth Professorship in Pathology. "I am considerably more optimistic of the utility of a genetically targeted therapy for pancreatic cancer today than when we began this work."
Pancreatic cancer is particularly difficult to treat, and is often diagnosed at a late stage when it is no longer amenable to surgical removal. Chemotherapy has a modest effect, and unfortunately the disease progresses in the vast majority of cases. Therefore, new therapeutic regimens are urgently needed.
"Pancreatic cancer will surpass breast and prostate to become the third-leading cause of cancer-related deaths in the next 15 years. If we want to change the death rate, we need to increase the investment in understanding the biology of pancreatic cancer and identifying novel treatment strategies," said co-author and pancreatic cancer surgeon Dr. Michael Choti, Chairman of Surgery, who holds the Hall and Mary Lucile Shannon Distinguished Chair in Surgery.
The study identified a multitude of events that could be selectively targeted in the context of individual pancreatic tumors. For example, the study defined cases of pancreatic cancer that are driven by a gene called BRAF, for which there are FDA-approved drugs, and showed that such drugs were selectively effective against BRAF-mutated pancreatic cancer cells. Similarly, they defined deficits in other features of the tumor cell that can be treated by select drugs.
While these are exciting discoveries for a disease with such a poor prognosis, Dr. Witkiewicz voiced caution.
"Most pancreatic cancers exhibit multiple genetic alterations; therefore, it is likely that combination approaches targeting multiple pathways will be required for effective disease control," she said.
Explore further: Promising new strategy to halt pancreatic cancer metastasis
Medical Xpress on facebook
Related Stories
Promising new strategy to halt pancreatic cancer metastasis
Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.
Researchers learning more about deadly pancreatic cancer
(HealthDay)—Scientists are working to find new ways to treat pancreatic cancer, one of the deadliest types of cancer in the United States.
What makes pancreatic cancer so aggressive? New study sheds light
New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.
Pancreatic cancer has four distinct types
Researchers have found that pancreatic cancer can be split into four unique types, a discovery that could be used to improve treatments for the disease, according to a study published in Nature.
Researchers identify pancreatic cancer patients who benefit from personalized treatment
Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.
Recommended for you
A downward trend for new cases of pediatric melanoma
Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has ...
We may be looking at wrong mutation for breast cancer treatment
A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to research published in open access journal Genome Medicine.
Genetic screening could improve breast cancer prevention
A test for a wide range of genetic risk factors could improve doctors' ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.
Biologists identify brain tumor weakness
Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.
No association between lung cancer risk in women and reproductive history or hormone use
The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for ...
Tumor cells that mimic blood vessels could help breast cancer spread to other sites
Imitation may be the sincerest form of flattery, but it can also have deadly consequences, at least when it comes to tumor cells.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment